Cargando…

Commentary on “Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes”

Detalles Bibliográficos
Autores principales:	Lin, Zhemin, Niu, Yinong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106250/ https://www.ncbi.nlm.nih.gov/pubmed/36914942 http://dx.doi.org/10.1097/CM9.0000000000002594

Ejemplares similares

Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes
por: Liu, Deli, et al.
Publicado: (2020)

Commentary on “Solving the benign prostatic hyperplasia puzzle”
por: Thomas, Dominique, et al.
Publicado: (2018)

Laparoscopic simple prostatectomy with prostatic urethra preservation for benign prostatic hyperplasia
por: Xing, Nianzeng, et al.
Publicado: (2012)

Commentary on “Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea”
por: Shin, Yu Seob, et al.
Publicado: (2021)

Benign Prostatic Hyperplasia
Publicado: (2015)

Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer
por: Chen, Fengju, et al.
Publicado: (2016)

Reply to Commentary on “Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea”
por: Jo, Jung Ki, et al.
Publicado: (2021)

Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast
por: Gatalica, Zoran, et al.
Publicado: (2015)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
por: Liu, Zhanliang, et al.
Publicado: (2022)

Multiplatform Molecular Profiling Reveals Epigenomic Intratumor Heterogeneity in Ependymoma
por: Liu, S. John, et al.
Publicado: (2020)

Integrative profiling of Epstein–Barr virus transcriptome using a multiplatform approach
por: Fülöp, Ádám, et al.
Publicado: (2022)

Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities
por: Suppiah, Suganth, et al.
Publicado: (2023)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Botulinum toxin and benign prostatic hyperplasia
por: Ng, Lay Guat
Publicado: (2018)

Solving the benign prostatic hyperplasia puzzle
por: Foo, Keong Tatt
Publicado: (2016)

Tissue microenvironment and benign prostatic hyperplasia
por: Wei, Xing, et al.
Publicado: (2019)

Commentary on PSP Subtypes in India
por: Behari, Madhuri
Publicado: (2021)

Commentary: Patent foramen ovale is not always a benign condition
por: Anselmi, Amedeo
Publicado: (2020)

Commentary: Juxtaposition of the atrial appendages: Fatal attraction or benign coupling?
por: Abdullah, Ibrahim
Publicado: (2021)

Multiplatform Programming with Python
por: Kicsiny, Peter
Publicado: (2023)

Safety profile of colocasia esculenta tuber extracts in benign prostate hyperplasia
por: Tusubira, Deusdedit, et al.
Publicado: (2023)

Multiplatform molecular analysis of vestibular schwannoma reveals two robust subgroups with distinct microenvironment
por: Landry, Alexander P., et al.
Publicado: (2023)

MULTIPLATFORM MOLECULAR ANALYSIS OF VESTIBULAR SCHWANNOMA REVEALS TWO ROBUST SUBGROUPS WITH DISTINCT MICROENVIRONMENT
por: Landry, Alexander P, et al.
Publicado: (2023)

Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia
por: SANCER, Okan, et al.
Publicado: (2022)

Prostatitis and benign prostatic hyperplasia: emerging infectious diseases?
por: Hennenfent, B
Publicado: (1997)

Zinc status in benign prostatic hyperplasia and prostate carcinoma
por: Wiwanitkit, Somsri, et al.
Publicado: (2012)

Linking Pre-Diabetes with Benign Prostate Hyperplasia. IGFBP-3: A Conductor of Benign Prostate Hyperplasia Development Orchestra?
por: Protopsaltis, Ioannis, et al.
Publicado: (2013)

Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma
por: Magill, Stephen T., et al.
Publicado: (2020)

Morphological Changes of Benign Prostatic Hyperplasia in Culture
por: McMahon, M. J., et al.
Publicado: (1973)

Benign Prostatic Hyperplasia: from Bench to Clinic
por: Yoo, Tag Keun, et al.
Publicado: (2012)

VASTI THERAPY IN THE MANAGEMENT OF BENIGN PROSTATE HYPERPLASIA
por: Gupta, Shivaji, et al.
Publicado: (1997)

Current Laser Treatments for Benign Prostatic Hyperplasia
por: Son, Hwancheol, et al.
Publicado: (2010)

Benign prostatic hyperplasia: An overview of existing treatment
por: Dhingra, Neelima, et al.
Publicado: (2011)

Therapeutic options in the treatment of benign prostatic hyperplasia
por: Sandhu, Jaspreet S
Publicado: (2009)

Unsolved Issues in Managing Benign Prostatic Hyperplasia
por: Oh, Seung-June
Publicado: (2013)

Recent advances in treatment for Benign Prostatic Hyperplasia
por: van Rij, Simon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6oue8duf8i84404vqh5597chd5